Skip to main content

Table 3 Distribution of clinicopathological parameters: CA IX positive versus CA IX negative high-risk breast cancer patients

From: Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials

   CA IX positive CA IX negative χ2/P value
All   151 (16%) 794 (84%)  
Protocol Pre (DBCG82b) 89 (59%) 447 (56%) 0.5
  Post (DBCG82c) 62 (41%) 347 (44%)  
Tumour size (mm) <21 48 (32%) 289 (36%) 0.5
  21 to 50 81 (54%) 393 (49%)  
  >50 22 (15%) 112 (14%)  
Positive nodes None 6 (3%) 50 (6%) 0.5
  1 to 3 70 (46%) 346 (44%)  
  >3 75 (50%) 398 (50%)  
Histopathology Ductal 133 (88%) 680 (86%) 0.4
  Nonductal 18 (12%) 114 (14%)  
Malignancy grade Grade 1 18 (12%) 166 (21%) P < 0.0001
  Grade 2 56 (37%) 357 (45%)  
  Grade 3 59 (39%) 157 (20%)  
  Nonductal 18 (12%) 114 (14%)  
ER Positive 50 (33%) 581 (73%) P < 0.0001
  Negative 101 (67%) 213 (27%)  
PgR Positive 47 (31%) 506 (64%) P < 0.0001
  Negative 104 (69%) 288 (36%)  
HER2 Negative 101 (33%) 636 (80%) P < 0.0001
  Positive 50 (67%) 636 (80%)  
  1. Shown is the distribution of various clinicopathological parameters among carbonic anhydrase (CA) IX positive and CA IX negative high-risk breast cancer patients randomized to receive or not receive postmastectomy radiotherapy. ER, oestrogen receptor; HER, human epidermal growth factor; PgR, progesterone receptor.